ScPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection
ScPharmaceuticals Enrolls First Participant In Pivotal Pharmacokinetic Study Of FUROSCIX Auto-Injector Injection
SCpharmicals 招募了第一位參與者 FUROSCIX 自動注射劑的關鍵藥代動力學研究
FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor
FUROSCIX 自動注射器是作爲 FUROSCIX 機身輸液器的補充而開發的
Company anticipates topline data in Q3 2024, followed by a Supplemental New Drug Application (sNDA) by year-end 2024, if successful
公司預計,關鍵數據將在2024年第三季度公佈,如果成功的話,將在2024年年底之前發佈補充新藥申請(snDa)